News Overview

EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortisation) during the quarter rose 32% to ₹4,820 crore.

In Q4FY25, net interest income (NII) came down 2% YoY at ₹1,563 crore, compared to ₹1,600 crore during the same period last year.

Dr Lal PathLabs declared a fourth interim dividend of ₹6 per share for 2025, reflecting its strong cash generation and shareholder remittance focus.

The company's top line, revenue from operations, declined 2.7% YoY at ₹778.8 crore in Q4 FY25, from ₹800.2 crore during the corresponding quarter of FY24.

EBITDA margin for the quarter stood at 15.7%, slightly lower than the 16.5% margin recorded in the corresponding period of the previous fiscal year.

The EBITDA of the company declined sharply to ₹21 crore, much lower than the ₹306.42 crore it clocked in the March quarter of the last financial year.

The company's net profit stood at ₹434.7 crore in Q4FY25, significantly higher compared to ₹140.3 crore recorded in the same quarter of the previous fiscal year.

UTI Multi Cap Fund offers higher risk-adjusted returns through a systematic exposure to mid-caps and small caps

Mahindra & Mahindra plans to establish a robust presence in the commercial vehicle segment exceeding 3.5 tonnes.

According to reports, the business is also planning its participation in the auction of all mineral blocks that will take place in India.